4-(benzyloxy)-2-methyl-1H-indole | 35308-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(benzyloxy)-2-methyl-1H-indole
• 英文别名: 4-Benzoyl-2-methyl-indol；4-benzyloxy-2-methyl-indole；2-methyl-4-benzyloxyindole；2-methyl-4-[(phenylmethyl)oxy]-1H-indole；2-methyl-4-phenylmethoxy-1H-indole
• CAS: 35308-72-6
• 化学式: C₁₆H₁₅NO
• 分子量: 237.301
• InChiKey: QGWACZFSCSTOCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(benzyloxy)-2-methyl-1H-indole 生成 2-(4-Benzyloxy-2-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide
  参考文献：
  名称：

  SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist

  摘要：

  An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.104

文献信息

• [EN] SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS<br/>[FR] 4-HYDROXY-N-(4-HYDROXYPHÉNYL)INDOLES SUBSTITUÉS EN TANT QU'AGENTS OETROGÈNES
  申请人：GLAXO GROUP LTD

  公开号：WO2009103710A1

  公开（公告）日：2009-08-27

  The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.

  本发明涉及具有药理活性的新型吲哚衍生物，其制备方法，含有它们的组合物以及这些化合物在治疗雌激素受体β介导的疾病中的应用。
• Compounds
  申请人：Glaxo Group Limited

  公开号：US07956083B2

  公开（公告）日：2011-06-07

  The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.

  本发明涉及具有药理活性的新型吲哚衍生物，其制备方法，包含它们的组合物以及这些化合物在治疗雌激素受体β介导的疾病中的应用。
• COMPOUNDS
  申请人：Johnson Christopher Norbert

  公开号：US20100324106A1

  公开（公告）日：2010-12-23

  The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.

  本发明涉及具有药理活性的新型吲哚衍生物，其制备方法，含有它们的组合物以及这些化合物在治疗雌激素受体β介导的疾病中的应用。
• [EN] 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'AMINE-INDOLE 3-CYCLIQUE UTILISÉS EN TANT QU'AGENTS SÉROTONERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：MINDSET PHARMA INC

  公开号：WO2022120475A1

  公开（公告）日：2022-06-16

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, and treating diseases, disorders or conditions treatable by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis and mental illness. (Formula (I))

  本申请涉及一般式(I)的3-环氨基吲哚衍生物，其制备过程，包含它们的组合物以及它们在细胞中激活5-羟色胺受体和治疗可通过细胞中5-羟色胺受体激活治疗的疾病、失调或病症的用途。这些疾病、失调或病症包括精神病和精神疾病。(式(I))
• SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY
  申请人：RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

  公开号：EP0548250A1

  公开（公告）日：1993-06-30